67199-13-7

Upstream product

• 117-34-0 2,2-diphenylacetic acid 
• 1871-76-7 diphenylacetic acid chloride 
• 67199-20-6 1-Diphenylacetyl-4-formylpiperazine 

Downstream Products

• 143210-50-8 2,2-Diphenyl-1-[4-(pyridine-3-carbonyl)-piperazin-1-yl]-ethanone 
• 143210-42-8 2,2-Diphenyl-1-(4-pyridin-3-ylmethyl-piperazin-1-yl)-ethanone 
• 129716-58-1 5-[3-(4-(2,2-diphenylacetyl)piperazine-1-yl)-2-hydroxypropoxy]quinoline 
• 1033443-30-9 5-(4-(2,2-diphenylacetoyl)piperazin-1-yl)-1-methyl-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-7(6H)-one 
• 137074-71-6 1-(diphenylacetyl)-4-(2-(pyridin-3-yl)-2-cyanoethyl)-piperazine 
• 137074-70-5 1-(diphenylacetyl)-4-(1-(pyridin-3-yl)-1-cyanoethyl)piperazine 
• 137075-32-2 1-(diphenylacetyl)-4-<2-(3-pyridyl)-2-hydroxoethyl>piperazine 
• 143840-91-9 1-[4-(2-Chloro-2-pyridin-3-yl-ethyl)-piperazin-1-yl]-2,2-diphenyl-ethanone 
• 143817-12-3 1-(4-Oxy-4-pyridin-3-ylmethyl-piperazin-1-yl)-2,2-diphenyl-ethanone 
• 137075-31-1 1-(diphenylacetyl)-4-<2-(3-pyridyl)-2-oxoethyl>piperidine 

Relevant academic research and scientific papers

Structure-activity relationship of newly synthesized quinoline derivatives for reversal of multidrug resistance in cancer

The effect of 24 newly synthesized quinoline derivatives on tumor cell multidrug resistance (MDR) was examined in vitro. At low concentrations, these compounds enhanced the accumulation of [3H]vincristine in K562/ADM cells and reversed tumor cell MDR. The results of the structure-activity relationship analysis indicate that in highly active compounds the two aryl rings in the hydrophobic moiety deviate from a common plane, so they are capable of interacting with hydrogen bond donors of P-170 glycoprotein (P- gp) via π-hydrogen-π interactions. Other major structural features which influence the MDR-reversing activities of these compounds are a quinoline nitrogen atom and a basic nitrogen atom in piperazine. Furthermore, in highly active compounds, the distance between the hydrophobic moiety and the basic nitrogen atom (an atom connected to 2-hydroxypropoxyquinoline) must be at least 5 A?. Several compounds were found to reverse vincristine resistance in K562/ADM cells in vitro, and compound 16 (MS-209) was selected for clinical studies.

(Pyridylcyanomethyl)piperazines as orally active PAF antagonists

A series of (pyridylcyanomethyl)piperazines was prepared and evaluated for PAF-antagonist activity. Compounds were tested in vitro in a PAF-induced platelet aggregation assay and in vivo in a PAF-induced hypotension test in normotensive rats. Oral activity was ascertained through a PAF-induced mortality test in mice. The main structure-activity trends of the series were established. Activity was mainly found in four skeletons: 1-acyl-4-(3- pyridylcyanomethyl)-piperazine, 1-acyl-4-(4-pyridylcyanomethyl)piperazine, 1- acyl-4-(3-pyridylcyanomethyl)piperidine, and 1-acyl-4-cyano-4-(3- pyridylamino)piperidine. The acyl substituents, diphenylacetyl and 3,3- diphenylpropionyl, provided the most active compounds, and the introduction of an amine or hydroxy group in the 3,3-diphenylpropionyl substituent led to further improvement in oral activity. As a result, three of the most active compounds (100, 114, and 115) have been selected for further pharmacological development.